ISSCR 2026-Healthgen Biotech showcases rice-derived rHSA

MONTREAL, July 8–11, 2026 – The International Society for Stem Cell Research (ISSCR), the world’s leading cross-disciplinary authority spanning over 80 countries, dedicated to advancing the translation of basic stem cell research into clinical applications, is holding its 2026 Annual Meeting in Montréal, Canada. Under the theme “Real Discoveries, Real Collaboration, Real Potential,” the flagship event convenes nearly 3,500 researchers, biopharma R&D leaders, CDMOs, upstream raw-material suppliers, and global regulatory experts to map the frontier of stem cell science and its clinical translation.

Since 2019, Healthgen Biotech has participated in ISSCR for multiple consecutive years, showcasing its innovative plant-derived recombinant human serum albumin (OsrHSA) solution based on a rice expression system to the global cell therapy community. The company has taken the lead in breaking the industry’s heavy reliance on traditional animal-derived BSA, delivering the animal-free, safer and high batch consistency domestic raw materials into the global stem-cell spotlight.

Fueled by a long-term internationalization strategy, Healthgen Biotech continues to deepen its footprint in stem cell and regenerative medicine, actively advancing global standards for serum-free culture systems, CGT process quality control, and clinical compliance. From global research to industrial pipelines, the company is steadily replacing animal-origin raw materials with plant-based recombinant proteins – raising the global profile and influence of China’s upstream biological raw materials.

As the global pioneer to industrialize plant-based recombinant human serum albumin, Healthgen Biotech holds both a clinical trial approval in China and a U.S. FDA Drug Master File (DMF) filing for its flagship product OsrHSA. This dual regulatory standing has drawn proactive partnership interest from biopharma developers, manufacturers, and supply-chain players worldwide. With each ISSCR appearance, Healthgen Biotech reinforces the global visibility of China’s original biotechnology breakthroughs and underscores the country’s accelerating momentum in biopharmaceutical innovation and international expansion.